We're built around a next-generation technology for bringing critical plasma-derived therapeutics to the people who need them.

People with many rare diseases rely on therapies made from proteins extracted from blood plasma. For more than 75 years, these proteins have been captured through a rudimentary yet expensive process. Until now.

Our patented next-generation technology is the first major advancement in the field in over 70 years. We believe it will help us deliver critical plasma-derived therapies at higher levels of purity, efficiency, and quality than conventional methods can.

Ultimately, Evolve aims to improve the lives of people within a largely underserved market—and build future shareholder value in the process.

Evolve Biologics is targeting three types of plasma-derived therapeutics. All three types have proven successful in addressing particular conditions.

We aim to commercialize plasma-derived therapeutics using our proprietary PlasmaCap EBA purification technology to more efficiently and effectively meet growing global patient demand for the products. Evolve is currently in the process of developing a portfolio of product candidates, and is using IVIG which is currently in a Phase III clinical trial, Albumin and AAT.

More information about our IVIG trial can be found at clinicaltrials.gov.

Our Pipeline

Our Process

01 The process begins by passing plasma through a series of chromatography columns, each arranged within a particular sequence.

02 Each column contains dense adsorbent beads of our own invention. By design, the target proteins bind to these beads, enabling them to be extracted at a high rate.

03 The fluidizer rotates gently as the plasma passes through, creating the optimal circumstances for protein binding. Unbound proteins continue to flow, retaining their structure so they can be captured later in the process.

04 Compared to legacy techniques, PlasmaCap EBA is designed to extract more valuable proteins from each liter of donor plasma. This ultimately opens the possibility of helping more people who need them—and doing it more reliably.

05 Compared to legacy techniques, PlasmaCap EBA is designed to extract more valuable proteins from each liter of donor plasma. This ultimately opens the possibility of helping more people who need them—and doing it more reliably.
Our Technology

PlasmaCap EBA®, Evolve’s proprietary and patented technology for protein extraction, plays a key role in our developing portfolio.

Thousands of proteins are found within human blood plasma. Many of these proteins have therapeutic value in treating a range of diseases, including immune deficiencies, autoimmune and neurological disorders, and hemophilia. Compared to legacy techniques, PlasmaCap EBA is designed to extract more valuable proteins from each liter of donor plasma. This ultimately opens the possibility of helping more people who need them—and doing it more efficiently.

Our Vision

We seek to deliver plasma-derived therapeutics at higher levels of purity, efficiency, and reliability than anyone in our industry.

As a first step toward achieving that vision, we have advanced the technology used to extract plasma proteins from blood. Our patented technique, PlasmaCap EBA®, is the first major improvement in this area in more than 75 years.

We believe this technique will allow us to achieve the quality of plasma-derived therapeutics that has the potential to extract more value from each liter of precious donor plasma as compared to legacy technology. And its efficiency drives reliability—in both quality and consistency of supply.

Because our technology is proprietary and protected, and we have direct control of our manufacturing, we expect our supply to be more consistent and predictable than today’s options.

We think it’s about time someone advanced the way biologics are delivered. So Evolve is doing just that.